UPDATE: TetraLogic Reports Temporary Halt of Chronic Hep B Trial

TetraLogic Pharmaceuticals Corporation TLOG, a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced that it has temporarily halted enrollment in the birinapant chronic hepatitis B multiple ascending dose trial, currently being conducted in Australia, due to cranial nerve palsies observed in the first cohort.